Guidelines: screen for lung cancer with low-dose CT

Share this article:

The American Association for Thoracic Surgery (AATS) is calling for annual lung cancer screening using low-dose computed tomography (LDCT) for North Americans aged 55 to 79 years with a 30 pack-year history of smoking in new guidelines published in Journal of Thoracic and Cardiovascular Surgery (2012;144:33-38).

The AATS also recommends that persons age 50 years and older with a 20 pack-year history undergo annual screening for lung cancer with LDCT if they have an additional cumulative risk of developing lung cancer of 5% or greater over the following 5 years. In addition, long-term survivors of lung cancer, defined as persons who have been treated for a primary bronchogenic carcinoma and have completed 4 years of radiographic surveillance without evidence of recurrence, should undergo annual LDCT to detect second primary lung cancer until they reach age 79 years.

“At this time and for the first time in medical history, we can say, ‘lung cancer screening—the time has come,'” wrote Michael T. Jaklitsch, MD, of Brigham and Women's Hospital, Boston, Massachusetts, and the other members of the AATS task force that developed the guidelines. The group credits LDCT for providing a useful screening method that has been proven to increase the survival of persons with lung cancer.

The AATS guidelines differ from those put forth by other organizations not only because the new document addresses survivors of lung cancer, but also because screening is recommended for persons up to age 79 years. Other societies recommend screening for patients only up to age 74 years. However, noted the AATS guideline authors, screening should not be performed in individuals of any age who have comorbidities or functional status that would prevent them from getting adequate treatment.

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Improved tyrosine kinase inhibitor (TKI) selectively activates in tumor tissue, minimizing side ...

A new strategy developed by an interdisciplinary team of researchers aims to reduce the side effects connected to use of tyrosine kinase inhibitors (TKIs).

Prior cancer exclusion criteria may stymie potential of lung cancer clinical trials

A history of prior cancer can exclude many individuals from participation in clinical trails related to lung cancer, even when the prior cancer is unlikely to interfere with treatment outcomes.

Better adherence to guidelines for safe handling of antineoplastic drugs is needed

Recommended safe handling practices for workers who administer antineoplastic drugs in health care settings are not always followed, according to a new study.